Virpax Pharmaceuticals Inc (VRPX) - Total Liabilities
Based on the latest financial reports, Virpax Pharmaceuticals Inc (VRPX) has total liabilities worth $2.47 Million USD as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VRPX cash generation efficiency to assess how effectively this company generates cash.
Virpax Pharmaceuticals Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Virpax Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Virpax Pharmaceuticals Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Virpax Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Virpax Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tan Delta Systems PLC
LSE:TAND
|
UK | GBX227.60K |
|
Sejahtera Bintang Abadi Textile Tbk
JK:SBAT
|
Indonesia | Rp495.54 Billion |
|
Groupimo SA
PA:ALIMO
|
France | €1.37 Million |
|
PCI Biotech Holding ASA
OL:PCIB
|
Norway | Nkr6.01 Million |
|
Stayble Therapeutics AB
ST:STABL
|
Sweden | Skr1.44 Million |
|
Baltic Bridge S.A.
WAR:WIS
|
Poland | zł6.36 Million |
|
M Winkworth PLC
LSE:WINK
|
UK | GBX2.79 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Virpax Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Virpax Pharmaceuticals Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Virpax Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Virpax Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Virpax Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.47 Billion | +31994.70% |
| 2023-12-31 | $7.69 Million | +148.63% |
| 2022-12-31 | $3.09 Million | +48.23% |
| 2021-12-31 | $2.09 Million | -55.41% |
| 2020-12-31 | $4.68 Million | +68.46% |
| 2019-12-31 | $2.78 Million | +121.57% |
| 2018-12-31 | $1.25 Million | -- |
About Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an … Read more